Treating Biliary Tract Cancers: New Targets and Therapies

• Published in: Drugs (New York, N.Y.) N.Y.), 2022-11, Vol.82 (17), p.1629-1647
• Main Authors: Ho, Joseph, Fiocco, Constance, Spencer, Kristen
• Format: Article
• Language: English
• Subjects: Abnormalities; Biliary tract; Biliary tract diseases; Cancer; Cancer therapies; Chemotherapy; Cholangiocarcinoma; Cisplatin; Clinical trials; Dehydrogenases; Epidermal growth factor; ErbB-2 protein; Fibroblast growth factor receptors; Gallbladder cancer; Gemcitabine; Growth factors; Immunotherapy; Internal Medicine; Isocitrate dehydrogenase; Leading Article; Medical prognosis; Medicine; Medicine & Public Health; Metastasis; Neutropenia; Pharmacology/Toxicology; Pharmacotherapy; Potassium; Receptors; Tumors
• ISSN: 0012-6667; 1179-1950
• DOI: 10.1007/s40265-022-01808-x

Biliary tract cancers (BTCs) are rare and aggressive tumors that typically present at an advanced stage when surgical resection is no longer considered a therapeutic option. While gemcitabine and cisplatin have been the mainstay of treatment, unique chemotherapy combination strategies, targeted therapies, and immunotherapies have had some clinical efficacy and remain promising areas for clinical research. The use of molecular profiling of BTCs has facilitated the development and subsequent clinical application of novel targeted therapy compounds. Among the many genomic alterations identified in BTCs, molecular abnormalities in the fibroblast growth factor receptor (FGFR), isocitrate dehydrogenase (IDH), human epidermal growth factor receptor 2 (HER2), and BRAF have been successfully targeted therapeutically in clinical trials. Furthermore, the expanded use of new chemotherapy combinations, targeted therapies, and immunotherapies into alternate clinical settings such as in the neoadjuvant and adjuvant spaces is an area of active investigation. The management of BTCs is rapidly evolving. In this article, we review the emerging targets and therapies in BTC.